ARROWHEAD PHARMACEUTICALS, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $10.14 million for the 12-month period ending 2015-09-30, per its 10-K filed 2017-12-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2017-12-12
- ARROWHEAD PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2015-09-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2015-06-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2015-03-31 was $10.14M.
- ARROWHEAD PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2015 was $10.14M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2015-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-12 | $0.00 derived: sum of 2 quarters · filed 2017-12-12 | $10.14M derived: sum of 3 quarters · filed 2017-12-12 | $10.14M 10-K · filed 2017-12-12 |
| 2015-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-09 | $10.14M derived: sum of 2 quarters · filed 2016-08-09 | $10.14M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $10.14M 10-Q · filed 2016-05-10 | $10.14M 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |